Published in Can J Cardiol on February 01, 2006
Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol (2013) 3.85
Cancer prevention with promising natural products: mechanisms of action and molecular targets. Anticancer Agents Med Chem (2012) 1.01
AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. Mol Cell Endocrinol (2010) 0.86
Lipoic acid supplementation and endothelial function. Br J Pharmacol (2008) 0.81
Athero-Inflammatory Nanotherapeutics: Ferulic Acid-based Poly(anhydride-ester) Nanoparticles Attenuate Foam Cell Formation by Regulating Macrophage Lipogenesis and Reactive Oxygen Species Generation. Acta Biomater (2017) 0.76
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med (1996) 10.09
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet (1996) 6.48
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med (1997) 4.51
Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A (1990) 4.34
Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest (1996) 3.64
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med (1995) 3.60
Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature (1990) 3.11
Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest (1993) 2.97
Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature (1990) 2.46
Oxidative stress as a regulator of gene expression in the vasculature. Circ Res (1999) 2.26
Vitamins C and E inhibit O2- production in the pig coronary artery. Circulation (1997) 2.14
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol (2001) 1.71
Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation (1998) 1.51
Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J (1992) 1.43
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol (2002) 1.29
The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem (1997) 1.23
Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet (1990) 1.20
Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation (2003) 1.09
Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol (1995) 1.08
Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest (1994) 1.07
Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest (1994) 1.06
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol (1994) 1.03
Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation (1993) 1.03
Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res (1994) 0.97
Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation (2003) 0.96
Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation (1999) 0.94
Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest (1993) 0.93
Intravascular ultrasound assessment of atherosclerosis. Curr Atheroscler Rep (2004) 0.89
Prevention of restenosis with antioxidants: mechanisms and implications. Am J Cardiovasc Drugs (2002) 0.89
AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther (2003) 0.89
Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci U S A (1992) 0.88
Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol (1997) 0.84
Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. J Am Coll Cardiol (1994) 0.83
Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am J Cardiol (2003) 0.83
Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther (2003) 0.83
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett (2002) 0.80
Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol (2003) 0.79
Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther (1993) 0.78
Modulation of the physical state of cellular cholesteryl esters by 4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (probucol). J Biol Chem (1992) 0.78
Insights into oxidative stress and atherosclerosis. Can J Cardiol (2000) 0.78
Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol (2001) 0.77
Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J (1996) 0.77
Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J (1996) 0.76